In VivoThe promise of mRNA therapeutics has been held back by a fundamental physical limitation: lipid nanoparticles containing mRNA are inherently fragile and prone to aggregation when subjected to the mech
ScripBristol Myers Squibb is following Merck & Co. and Pfizer by buying into the bispecific PD-L1xVEGF-targeting mechanism for cancer, announcing on June 2 that it will pay $1.5bn up front to BioNTech
Pink SheetConfused and alarmed stakeholders worry that Health and Human Services Secretary Robert F. Kennedy Jr. usurped a role long played by the US Centers for Disease Control and Prevention and its external
ScripMarket analysts have deemed the US Food and Drug Administration’s COVID-19 vaccine policy unveiled 20 May as far from a worst-case scenario for vaccine-focused firms – for example, approved vaccines w